Event Type: CLE / CPD
- Location Name:
- Reed Smith's Philadelphia Office, Three Logan Square Suite 3100 1717 Arch Street, Philadelphia PA 19103
- Start Date/Time:
- 10 November 2016, 8:30 AM ET
- End Date/Time:
- 10 November 2016, 2:30 PM ET
Reed Smith’s Life Sciences Health Industry Group is pleased to offer a 1/2-day CLE covering hot topics and emerging litigation trends for in-house counsel.
Please join us for informative and practical sessions on Product Liability, Government Enforcement, Intellectual Property and Insurance issues impacting our pharmaceutical and medical device clients.
Sessions will include:
- Major Drug and Device Decisions of 2016
Presented by Eric Alexander (partner, Reed Smith LLP) and Kelly Hibbert (associate, Reed Smith LLP) - FCA Post-Escobar: Materiality Matters
Presented by Thomas Suddath (partner, Reed Smith LLP), Brian Himmel (partner, Reed Smith LLP), and Lindsey Harteis (associate, Reed Smith LLP) - Purple is the New Orange: A Primer on the Biologics-Biosimilars Landscape
Presented by Lisa Chiarini (partner, Reed Smith LLP) and Rudolf Hutz (counsel, Reed Smith LLP) - Looking for Law in All the Wrong Places: Perspectives on the Best (and Worst) Product Liability Jurisdictions
Presented by Rick Fuentes, Ph.D. (jury consultant, R&D Strategic Solutions), Barbara Binis (partner, Reed Smith LLP), Melissa Geist (partner, Reed Smith LLP), and Marilyn Moberg (partner, Reed Smith LLP) - Regulating Healthcare on a New Wavelength: The FCC’s Role In Wireless Medical Devices
Presented by Paul Bond (partner, Reed Smith LLP) and Samuel Cullari (counsel, Reed Smith LLP) - Implied Preemption – It’s Not Just for Generic Drugs Anymore (Plus Off-Label Promotions Update)
Presented by James Beck (counsel, Reed Smith LLP) and Rachel Weil (counsel, Reed Smith LLP)
This program is geared toward in-house counsel; space is limited.